The protein-based vaccine, after two Phase III clinical trials involving over 3,000 participants, was found to be safe, at least 90% effective in preventing symptomatic cases of the original coronavirus strain, and at least 80% effective in preventing symptomatic cases of the delta variant.
The vaccine will be deployed in other underserved countries following India, according to a news release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.